|
 Canada's Valeant said it remained committed to
getting the deal done but would remain "financially disciplined."
Allergan, which makes the popular anti-wrinkle treatment Botox, said
on Monday that Valeant's business model was unsustainable and the
offer was too risky because of uncertainty about the company's
long-term growth.
(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb
Chakrabarty)
[to top of second column] |
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
